|  |
| --- |
| **Social determinants of health in clinical trials of long-term oral antibiotics in COPD: a systematic review** |
| Zac Irwin,1 Dr Amy Pascoe,2 Harrison Birch1, Meghan Owens-Reed1, A/Prof Natasha Smallwood2,3 |
| *1Melbourne Medical School, The University of Melbourne, Parkville, VIC**2Respiratory Research @ Alfred, Central Clinical School, Monash University, Prahran, VIC**3Department of Sleep and Respiratory Medicine, Alfred Health, Prahran VIC* |
| **Introduction/Aim:** Social determinants of health (SDH) including age, gender, ethnicity, socioeconomic status, education, occupation, and rural status have important effects on the development and prognosis of chronic obstructive pulmonary disease (COPD). It is currently unclear whether SDH are reported or considered in clinical trials looking at long-term oral antibiotics (LTOA) in COPD, and whether these interventions are meeting the needs of a diverse patient population. This review aimed to investigate the reporting and active consideration of SDH in clinical trials of LTOA in people with COPD.**Methods:** A search of four registries (clinicaltrials.gov, ANZCTR, ISRCTN, and CENTRAL) was conducted for clinical trials investigating LTOA in people with COPD with start dates between 2000-2023. Data were extracted regarding trial location, recruitment strategies, SDH and eligibility criteria. If trials were completed and published, SDH data were also extracted from associated published papers.**Results:** Of 781 trials identified, 20 trials were included in this review. Trials were primarily conducted in high-income countries (95%) and most described target age range (95%) and sex (95%) in recruitment information. Target ethnicity was rarely described (10%) and no trials described any other target SDH of interest. Of completed trials with published results (n=9), all reported age and sex of participants, three (33.3%) reported ethnicity, and none reported any other SDH. A total of 3409 participants were included in published results, with a minimum average age of 64.7 years and 36.3% were female. In the three trials reporting ethnicity, participants were predominantly White (73% to 99%).**Conclusion:** SDH are under-reported in clinical trials investigating the use of LTOA in people with COPD, and when reported, highlight a lack of diversity in recruited participants. Future research should aim to actively consider and report SDH to better understand the impacts of SDH on COPD and the appropriateness of LTOA on diverse patient populations.**Grant support:** nil.**Conflict of interest:** nil. **Grant Support:**  |